Technical Analysis for LVCLY - Living Cell Tech ADR

Grade Last Price % Change Price Change
F 0.09 0.00% 0.0000
LVCLY closed unchanged on Wednesday, May 5, 2021, on 28 percent of normal volume. Note that the stock is in oversold territory based on its Slow Stochastic indicator (14, 3, 3) -- sideways movement or a bounce should not be unexpected.

Trend Table & Recent EOD Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Down Down Down
Historical LVCLY trend table...

Date Alert Name Type % Chg
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.00%
Stochastic Buy Signal Bullish 0.00%
Narrow Range Bar Range Contraction 0.00%
Wide Bands Range Expansion 0.00%
Oversold Stochastic Weakness 0.00%
Narrow Range Bar Range Contraction 0.00%
Older End-of-Day Signals for LVCLY ...

   Recent Intraday Alerts -- Get these alerts pushed to you via our Mobile App

Alert Time
No Alerts Yet. Alerts will only show here if at least one person is tracking alerts on this stock.
View Earlier Intraday Alerts

Get a Trading Assistant

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

Living Cell Tech ADR Description

Living Cell Technologies Limited (LCT) is an Australasian biotechnology company improving the wellbeing of people with serious diseases worldwide by discovering, developing and commercializing regenerative treatments which restore function using naturally occurring cells. LCT's lead product NTCELL is an alginate coated capsule containing clusters of neonatal porcine choroid plexus cells. After transplantation, NTCELL functions as a biological factory producing nerve growth factors to promote new central nervous system growth and repair disease induced nerve degeneration. The Phase I/IIa NTCELL clinical trial in New Zealand for the treatment of Parkinson's disease met the primary endpoint of safety and showed encouraging clinical efficacy improvements. Results from this trial will be used to design a larger Phase IIb trial to evaluate its potential as a disease-modifying treatment for patients with Parkinson's disease. It has the potential to be used in a number of other central nervous system indications such as Huntington's, Alzheimer's and motor neurone diseases. LCT's proprietary encapsulation technology, IMMUPEL, allows cell therapies to be used without the need for co-treatment with drugs that suppress the immune system. LCT holds a 50% interest in Diatranz Otsuka Limited which is developing a cell therapy for type 1 diabetes. LCT is listed on the Australian (ASX: LCT) and US (OTCQX: LVCLY) stock exchanges. The company is incorporated in Australia, with its operations based in New Zealand.


Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biology Life Sciences Diabetes Immune System Stem Cells Stock Exchanges Cell Biology Parkinson's Disease Restore Cell Therapy Encapsulation Nerve Huntington Natal Transplantation Treatment Of Parkinson's Disease The Australian Alzheimer's Lexus Growth Factors Type 1 Diabetes Serious Diseases New Zealand Encapsulation Technology Motor Neurone Diseases Repair Disease Treatment For Patients With Parkinson's Disease

Is LVCLY a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Recent News

Indicators

Indicator Value
52 Week High 0.3825
52 Week Low 0.05
Average Volume 6,398
200-Day Moving Average 0.1262
50-Day Moving Average 0.1059
20-Day Moving Average 0.1061
10-Day Moving Average 0.0913
Average True Range 0.0129
ADX 11.93
+DI 29.5884
-DI 35.2614
Chandelier Exit (Long, 3 ATRs ) 0.1288
Chandelier Exit (Short, 3 ATRs ) 0.1262
Upper Bollinger Band 0.1466
Lower Bollinger Band 0.0656
Percent B (%b) 0.3
BandWidth 76.3431
MACD Line -0.0070
MACD Signal Line -0.0050
MACD Histogram -0.002
Fundamentals Value
Market Cap 5.14 Million
Num Shares 57.1 Million
EPS
Price-to-Sales 2453.14
Price-to-Book 2.70
PEG Ratio 0.00
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 0.0975
Resistance 3 (R3) 0.0983 0.0967 0.0963
Resistance 2 (R2) 0.0967 0.0948 0.0963 0.0958
Resistance 1 (R1) 0.0933 0.0936 0.0925 0.0925 0.0954
Pivot Point 0.0917 0.0917 0.0913 0.0913 0.0917
Support 1 (S1) 0.0883 0.0898 0.0875 0.0875 0.0846
Support 2 (S2) 0.0867 0.0886 0.0863 0.0842
Support 3 (S3) 0.0833 0.0867 0.0838
Support 4 (S4) 0.0825